Tranexamic Acid Has a Melasma Evidence File. The Route Changes the Risk and the Result.

Tranexamic acid has earned its place in the pigment conversation. It has not earned the right to be discussed as though it were one treatment.

The same molecule sits in brightening serums on the shelf and in the hands of dermatologists using it orally, intradermally and through procedure-assisted delivery for selected melasma patients. That is an unusually easy setup for an evidence-transfer mistake, and it happens constantly.

METHOD · EVIDENCEWhere the proof is standing.

Systematic reviewWhat a verdict wants: people, randomized, followed long enough for the effect to be real rather than new.
Randomized trialWhat a verdict wants: people, randomized, followed long enough for the effect to be real rather than new.
Small human trialWhat a verdict wants: people, randomized, followed long enough for the effect to be real rather than new.
Case seriesWhat the box usually cites. Real research, but a long way from your face — a reason to look, never proof.
Animal modelWhat the box usually cites. Real research, but a long way from your face — a reason to look, never proof.
In vitroWhat the box usually cites. Real research, but a long way from your face — a reason to look, never proof.

Nothing here is worthless. The question is only ever how far it is from the promise on the label.

Where the proof is standing. The ordinary hierarchy of study design. Marketing tends to cite the lower half and describe it in the language of the upper half; the gap between the two is where most of the work is.

A topical cosmetic and an oral prescription are not the strong and mild versions of the same routine. Route changes exposure, evidence, regulation, contraindications, and the entire character of the decision you are making.

Start with the original drug, not the serum bottle

Tranexamic acid is an antifibrinolytic drug. Current U.S. oral labeling is for cyclic heavy menstrual bleeding, not melasma. Using it orally for melasma is an off-label medical use requiring individualized risk assessment.

That matters because beauty content tends to present oral TXA as the strongest tier of a pigment ingredient, as though the serum, the tablet and the syringe were rungs on one ladder. It is more accurate to call it a different medical intervention that happens to share a name.

Melasma is where the evidence is most developed

Randomized trials and multiple meta-analyses support tranexamic acid as a potentially effective option in melasma. The effect has been studied through oral, topical, intradermal and microneedling-assisted routes, frequently alongside sunscreen or other treatment.

The load-bearing word is melasma. Evidence in a chronic pigment disorder does not quietly validate every cosmetic claim about generic dark spots, dullness, freckles or post-acne marks — even though those are the words on most of the packaging.

Oral TXA has the strongest signal in several analyses, and the highest medical burden

Meta-analyses comparing routes have often found stronger or faster improvement with oral treatment than with topical, though heterogeneity across studies is substantial. A placebo-controlled trial of oral TXA in moderate-to-severe melasma found greater improvement than placebo at three months.

That efficacy signal cannot be detached from systemic exposure. Current U.S. prescribing information lists thromboembolic disease, a history or intrinsic risk of thrombosis, and concomitant combined hormonal contraception among contraindications for the labeled oral product. Retinal vascular occlusion and other thromboembolic events appear in the warnings.

This is not a “check with your provider” footnote stapled to a skincare tip. It is the reason oral TXA belongs to a clinician-led decision, with your actual history in the room.

The melasma doses in studies do not rewrite the FDA label

Published melasma trials commonly use oral regimens that differ from the currently labeled U.S. dosing for heavy menstrual bleeding. That is ordinary in off-label research, and it is precisely why consumer articles have no business converting study doses into instructions.

Vanity or Vice can tell you oral TXA has been studied for melasma. It cannot prescribe a regimen, and a favorable meta-analysis does not resolve your clotting risk, your medication interactions, renal considerations, or pregnancy questions.

Topical TXA is appealing because the burden is smaller. The evidence is also less tidy.

Topical TXA has shown benefit in some randomized and comparative melasma studies, including formulas around 5% and higher. Other trials have found little or no difference from vehicle. Meta-analyses have produced similarly mixed estimates for topical treatment, partly because formulas, concentrations, comparators, combination therapy, skin types and study designs all vary.

That is not evidence that topical TXA is useless. It is evidence against pretending “5% tranexamic acid” describes a standardized treatment.

Ten percent is not automatically twice the treatment

One randomized trial comparing intradermal TXA concentrations against a 10% topical cream found much larger improvement in the intradermal groups than in the topical arm. A separate randomized split-face study of 5% topical TXA found no significant difference from vehicle.

Together they make a point worth carrying to every pigment product you consider: concentration is not the only variable, and it is rarely the decisive one. Vehicle, penetration, route, adherence, combination therapy and baseline disease all get a vote.

Intradermal and microneedling delivery move this out of ordinary skincare

Recent systematic review work suggests intradermal injection and microneedling-assisted TXA can be effective in melasma. But once a needle or a procedural device enters the picture, the treatment inherits procedure-level questions: sterility, product identity, concentration, delivery depth, provider scope, infection risk, pigment risk and complication management.

A serum formulated for intact skin does not become an appropriate needling solution because both things mention TXA on the label.

Post-inflammatory hyperpigmentation is promising, and it is not melasma

Tranexamic acid comes up more and more for PIH and other hyperpigmentation disorders. The biology is plausible and the clinical literature is growing. Melasma and PIH still have different triggers, different recurrence patterns and different treatment priorities.

For PIH in particular, stopping the inflammation that keeps generating new pigment usually matters more than adding a more fashionable brightening active on top of it.

Visible-light protection still belongs in the plan

Melasma management is not an ingredient competition. Photoprotection remains foundational, and recent consensus work increasingly includes visible-light-aware strategies for appropriate patients, particularly where recurrence is the problem.

A $120 TXA serum paired with casual sun protection is a very expensive way to skip the least glamorous requirement in the plan. It is also an extremely common way to do it, because buying the serum feels like action and reorganizing your relationship with daylight does not.

Where topical TXA fits best

A topical TXA product is easiest to defend when it makes a narrow cosmetic promise, uses a tolerable vehicle, discloses its concentration where that means something, and ideally brings finished-formula data. It gets much harder to defend when the product page cites oral or injected melasma studies as proof that the retail serum will deliver the same magnitude of change.

Route is part of the evidence. It should stay attached to the claim.

Questions worth asking before buying, booking, or taking TXA

What pigment problem is being treated? Melasma, PIH, solar lentigines and an unexplained changing lesion are not the same job.
What route? Topical cosmetic, compounded topical, oral prescription, intradermal injection and procedure-assisted delivery each need their own evidence and safety review.
What exact formula or product was studied? Ingredient-level evidence should not silently become product-level proof.
What is the recurrence plan? Melasma usually requires ongoing trigger management and maintenance.
For oral use, what changes thrombotic risk? That belongs to a medical history and medication review, not an online checklist.

The Verdict

Vanity: tranexamic acid is one of the more scientifically interesting additions to modern pigment care. It has moved well past mechanism-only skincare into a substantial clinical literature.

Vice: the same molecule turns up in a serum, a tablet, a syringe and a microneedling protocol, which makes it dangerously easy to file route under minor detail. It is not a minor detail. It is most of the decision.

Topical TXA can be a reasonable pigment ingredient. Oral and injected TXA are medical interventions. Keep the evidence attached to the route and this category becomes far easier to judge.

Sources worth opening

Method note: Oral, injected, and procedure-assisted TXA are medical topics. This article explains evidence and route differences and does not provide individualized treatment or dosing. It follows the Vanity or Vice Editorial Standards.

Part of Routines & Ingredients.